Cipaglucosidase alfa Drug Asset Due Diligence Report 2026

This Cipaglucosidase alfa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Cipaglucosidase alfa can convert its Enzyme profile and Glycogen biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Cipaglucosidase alfa (query alias: cipaglucosidase alfa)
Modality / target	Enzyme; Glycogen; Alpha glucosidase replacements
Highest global status	Approved
Originator	Amicus Therapeutics, Inc.
Active developers	Amicus Therapeutics Europe Ltd., Amicus Therapeutics, Inc., Amicus Therapeutics US LLC

The MCP disease footprint includes Glycogen Storage Disease Type II. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT04808505	Phase 3	Recruiting	36	Proportion of subjects with infusion-associated reactions (IARs)
NCT06121011	Not Applicable	Recruiting	500	Evaluate long-term safety of Pompe disease treatments
JPRN-jRCT2061210056	Not Applicable	Not Recruiting	10	To evaluate the safety of ATB200/AT2221 co-administration

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

90-month pulmonary function outcomes with cipaglucosidase alfa+miglustat in adults with Pompe disease in ATB200-02, an open-label phase I/II study

Phase 1/2; n=29; evaluation: Positive. Reported fields: ppFVC(month 60) = 5.0 % ( 8.07); -

A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease (LOPD)

Phase 3; n=119; evaluation: not stated. Reported fields: Subjects with TEAEs = 37 Participants ; Subjects with TEAEs = 80 Participants ; -

Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials

Phase 3; n=151; evaluation: Positive. Reported fields: IRR = 1.3 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Cipaglucosidase alfa addresses Glycogen Storage Disease Type II. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Enzyme—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-12-19	BioMarin Completes Acquisition of Amicus Therapeutics	Approved	US$4,800.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO